[1]Patent:WO2010/68262,2010,A1.Locationinpatent:Page/Pagecolumn20
[2]Patent:JP5848595,2016,B2.Locationinpatent:Paragraph0035;0040
[3]Patent:WO2017/46131,2017,A1.Locationinpatent:Page/Pagecolumn29
[4]Patent:WO2016/16279,2016,A1.Locationinpatent:Page/Pagecolumn38
[5]OrganicProcessResearchandDevelopment,2016,vol.20,p.1461-1468
[6]Patent:WO2015/177537,2015,A1.Locationinpatent:Page/Pagecolumn45
[7]Patent:WO2019/159199,2019,A1.Locationinpatent:Page/Pagecolumn35;36;37;39
[8]Patent:WO2015/138933,2015,A1.Locationinpatent:Page/Pagecolumn22;23
[9]Patent:WO2015/110897,2015,A3.Locationinpatent:Paragraph00282-00284
[10]Patent:WO2015/118460,2015,A1.Locationinpatent:Page/Pagecolumn9
[11]Patent:WO2016/125192,2016,A2.Locationinpatent:Page/Pagecolumn34
[12]Patent:WO2017/29642,2017,A2.Locationinpatent:Page/Pagecolumn17
[13]Patent:WO2019/48808,2019,A1.Locationinpatent:Page/Pagecolumn31;32;33;34
[14]OrganicProcessResearchandDevelopment,2019,vol.23,p.558-564
[1]Patent:WO2015/19310,2015,A1
[2]Patent:WO2016/125192,2016,A2
[3]Patent:WO2016/125192,2016,A2
[1]Patent:WO2015/19310,2015,A1
[1]Patent:WO2015/19310,2015,A1
[1]Patent:WO2015/19310,2015,A1
Title: Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Journal: Antimicrobial agents and chemotherapy 20171201
Title: Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
Journal: Antimicrobial agents and chemotherapy 20170801
Title: Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Journal: Antimicrobial agents and chemotherapy 20150101
Title: Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
Journal: Clinical pharmacokinetics 20131101
Title: Dolutegravir (Tivicay) for HIV.
Journal: The Medical letter on drugs and therapeutics 20130930
Title: Dolutegravir: first global approval.
Journal: Drugs 20130901
Title: Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Journal: Lancet (London, England) 20130824
Title: Antiretroviral therapy: dolutegravir sets SAIL(ING).
Journal: Lancet (London, England) 20130824
Title: In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20130201
Title: The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.
Journal: Journal of acquired immune deficiency syndromes (1999) 20121101
Title: Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20121001
Title: The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
Journal: Current opinion in HIV and AIDS 20120901
Title: Pharmacology of HIV integrase inhibitors.
Journal: Current opinion in HIV and AIDS 20120901
Title: HIV integrase inhibitors in ART-experienced patients.
Journal: Current opinion in HIV and AIDS 20120901
Title: Tolerability of HIV integrase inhibitors.
Journal: Current opinion in HIV and AIDS 20120901
Title: From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Journal: Journal of pharmacokinetics and pharmacodynamics 20120801
Title: Update on raltegravir and the development of new integrase strand transfer inhibitors.
Journal: Southern medical journal 20120701
Title: Dolutegravir for the treatment of HIV.
Journal: Expert opinion on investigational drugs 20120401
Title: Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Journal: Pharmacotherapy 20120401
Title: Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
Journal: The Lancet. Infectious diseases 20120201
Title: Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Journal: Intervirology 20120101
Title: Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
Journal: The Journal of infectious diseases 20111201
Title: Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
Journal: Molecular pharmacology 20111001
Title: Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Journal: AIDS (London, England) 20110910
Title: Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Journal: British journal of clinical pharmacology 20110701
Title: Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Journal: The Journal of antimicrobial chemotherapy 20110701
Title: Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.
Journal: The Journal of antimicrobial chemotherapy 20110701
Title: S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.
Journal: Expert opinion on investigational drugs 20110401
Title: In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Journal: Antimicrobial agents and chemotherapy 20110201
Title: Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572).
Journal: Bioscience trends 20110101
Title: Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
Journal: Antimicrobial agents and chemotherapy 20100101
Title: Kobayashi M, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011 Feb;55(2):813-21.
Title: Moss L, et al. The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. Xenobiotica. 2015 Jan;45(1):60-70.
Title: Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72.
